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Abstract
Background: Virus-like particles (VLPs) formed by the human papillomavirus (HPV) L1 capsid
protein are currently being tested in clinical trials as prophylactic vaccines against genital warts and
cervical cancer. The efficacy of these vaccines is critically dependent upon L1 type-specific
conformational epitopes. To investigate the molecular determinants of the HPV16 L1
conformational epitope recognized by monoclonal antibody 16A, we utilized a domain-swapping
approach to generate a series of L1 proteins composed of a canine oral papillomavirus (COPV) L1
backbone containing different regions of HPV16 L1.
Results:  Gross domain swaps, which did not alter the ability of L1 to assemble into VLPs,
demonstrated that the L1 N-terminus encodes at least a component of the 16A antigenic
determinant. Finer epitope mapping, using GST-L1 fusion proteins, mapped the 16A epitope to the
L1 variable regions I and possibly II within the N-terminus.
Conclusions:  These results suggest that non-contiguous loop regions of L1 display critical
components of a type-specific, conformational epitope.
Background
Cervical carcinoma is the second leading cause of cancer
deaths in women worldwide and approximately 500,000
new case are diagnosed annually. While regular cytologi-
cal screening has greatly decreased mortality rates in
developed countries, the death rates for this cancer in
developing countries remains high due to the limited
availability of reliable screening and medical follow-up.
Clearly a preventive approach to this cancer is a feasible
and desired goal [1-6]. Animal studies have demonstrated
that vaccination with the papillomavirus L1 protein is
highly efficacious in preventing experimental viral infec-
tion and tumor formation [7-11]. As a consequence,
human trials are now in progress to assess the ability of
this vaccine to combat cervical cancer [4-6,12,13].
Serological studies of papillomavirus virus like particles
(VLPs) demonstrate that antibodies cross-reactive with
multiple HPV VLP types recognize type-common epitopes
and generally are not neutralizing. This has been shown
with both monoclonal antibodies and with polyclonal
sera [14-20]. In these studies, only highly homologous
HPVs, such as HPV6/11 and HPV18/45, induced cross-
neutralizing sera and type-common epitopes were found
to be less immunogenic than type-specific epitopes. These
observations have also been made in studies of human
sera. Women infected with one HPV type are not cross-
protected against infections with other HPVs and fre-
quently, multiple HPV infections co-exist in the same
patient [21-24]. This suggests that different papillomavi-
rus genotypes may represent different serotypes and that
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neutralizing antibody responses to different papillomavi-
ruses are type-specific.
Although HPV16 is the most common HPV type impli-
cated in cervical cancer development, as it is detected in
50% of cervical cancers [1], other high-risk HPVs com-
prise the remaining 50%. The future vaccine will have to
be multivalent in order to provide adequate protection,
perhaps consisting of a cocktail of different HPV neutral-
izing epitopes. For the successful development and imple-
mentation of a broadly protective, prophylactic HPV
vaccine, an understanding of the apparent serotypic-spe-
cific immune responses to different HPVs is paramount.
The recently published crystallography model predicts the
existence of loop structures that are displayed on the sur-
face of assembled capsomeres [25]. Sequence alignment
of 52 papillomavirus L1 proteins from different host spe-
cies demonstrates that there is considerable homology
with the exception of 5 hypervariable regions, each rang-
ing from 10 to 30 amino acids in length and located
within a surface-exposed loop. Both conformational and
linear papillomavirus epitopes recognized by neutralizing
antibodies have been mapped to the loops [14,26-34].
The loop domains can also present non-L1 peptides and
direct immune responses specifically toward these foreign
peptide sequences [34-37]. Not only do the papillomavi-
rus loop sequences display potentially virus-neutralizing
B cell epitopes, but the manner in which they are pre-
sented to the host immune system makes them highly
immunogenic. Given that the crystallography model pre-
dicts the hypervariable regions to be displayed as surface-
exposed loops [25]and that the loops are highly immuno-
genic, it is quite likely that the loop epitopes are the deter-
minants of type-specificity.
To directly address the issue of type-specificity, we utilized
a domain-swapping approach to generate a series of L1
proteins composed of a canine oral papillomavirus
(COPV) L1 backbone containing different regions of
HPV16 L1. Specifically, both gross and fine domain swaps
were performed in which different combinations of the 5
hypervariable regions from the surface-exposed loops of
HPV16 L1 were homologously swapped onto a COPV L1
backbone (Figure 1). This particular combination of L1s
was chosen for several reasons. First, HPV16L1-specific
monoclonal antibodies are available. Second, gross
HPV16-COPV L1 chimeras have been expressed as VLPs
[38], indicating that enough homology exists between the
divergent L1s to direct proper folding. Third, the COPV L1
backbone is of a different animal papillomavirus type and
therefore might provide the optimal signal-to-noise ratio.
Studies have been done on HPV hybrids [28,32,33] and
given the relative degree of conservation between these
HPV L1s, the resolution of these mapping studies may be
a confounding variable. We chose to test our hypothesis
by using the HPV16 VLP-specific antibody 16A, which rec-
ognizes a surface-exposed, serotype-specific, conforma-
tional epitope ([39] and unpublished observations). Our
study suggested that the epitope recognized by the HPV16
VLP-specific antibody 16A resides on the hypervariable
regions of loops I and possibly II.
Results
The anti-HPV16 monoconal antibody 16A recognizes a 
surface-exposed, conformational epitope
The immunological properties of the HPV16 L1-specific
monoclonal antibody 16A [39] were characterized by
ELISA, the results of which are shown Figure 1. The mon-
oclonal antibody 16A is strongly immunoreactive with
intact HPV16 L1 VLPs, but is non-reactive with either
denatured HPV16 L1 protein or with intact COPV L1
VLPs, demonstrating that 16A recognizes a conformation-
dependent epitope presented on the surface of intact
HPV16 VLPs. 16A does not react with HPV18, HPV11 or
HPV6 VLPs (unpublished observations). This mono-
clonal antibody is not neutralizing (data not shown).
The first 169 amino acids of HPV L1 are important for 16A 
antibody binding
The recently published crystallography model predicts the
existence of loop structures that are displayed on the sur-
face of assembled capsomeres [25]. A diagram of the rela-
tive positions, corresponding amino acids and numerical
designations for the 5 hypervariable regions of the sur-
face-exposed loop domains of L1, is shown in Figure 2a.
To evaluate the role of various L1 domains in conforma-
tional epitope formation, chimeric L1 proteins expressed
in Sf9 cells were tested by immunofluoresence micros-
copy using the HPV16 L1-specific, conformation-depend-
ent monoclonal antibody 16A (Figure 2d). BB22 is a
hybrid protein in which the first 169 amino acids of
COPV L1, encompassing hypervariable regions I and II,
replace those of HPV16 L1. Thus, the chimera contains
COPV L1 hypervariable regions I and II and HPV16 L1
hypervariable regions III, IV and V. In BB23, the ultimate
C-terminal 106 amino acids are of COPV L1 origin, and
therefore, all 5 HPV16 L1 hypervariable regions are
present. To evaluate whether the chimeric L1 proteins can
still assemble into VLPs, particles were purified from Sf9
cells expressing wild-type, BB22 or BB23 L1 constructs
and visualized using transmission electron microscopy
(TEM). BB22 and BB23 form VLPs similar in size and
shape to that of wild type HPV16 L1 (Figure 2b).
The conformation-independent monoclonal antibody,
AU1, which recognizes a linear, 6 amino acid epitope
found at the C-terminus of many different papillomavirus
L1 proteins [40]was used to detect expression of L1 con-
structs in Sf9 cells. As shown in Figure 2c, the expressionBMC Microbiology 2004, 4:29 http://www.biomedcentral.com/1471-2180/4/29
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level of the wild type HPV16 L1 and the different chimeric
proteins were similar. Figure 2d demonstrates that BB23 is
immunoreactive with antibody 16A in a pattern similar to
that of wild type HPV16 L1, whereas BB22 is non-reactive.
Taken together, these results suggest that the epitope rec-
ognized by 16A may be located within the first 169 amino
acids of HPV16 L1. However, they do not exclude the pos-
sibility that other regions of L1 might be involved in the
formation of the 16A epitope.
COPV L1 mutant with a five-loop sequence swap reacts 
with HPV antibody 16A
To directly investigate the hypothesis that the hypervaria-
ble regions of the loop domains are involved in the forma-
tion of type-specific, conformation-dependent epitopes,
the 5 discrete hypervariable regions from the surface-
exposed loop domains of HPV16 L1 were homologously
swapped onto the COPV L1 backbone. Due to the ease of
preparation, the GST-L1 fusion protein method was used
to complete the study. After purification, GST-L1 fusion
proteins assemble into capsomeres [7,41]. The GST tag
neither interferes with capsomere assembly, nor with
epitope presentation, as the GST-L1 preparation was pro-
tective as a vaccine [7].
The morphology and size of D12345 GST-L1 capsomeres
is comparable to wild type COPV GST-L1 and HPV16
GST-L1 capsomeres (Figure 3a). As electron microscopy
only evaluates morphology, sucrose density sedimenta-
tion analysis was used to verify that D12345 GST-L1 was
assembling into capsomeric structures. It has been shown
that COPV GST-L1 capsomeres sediment from 12–16 S
[7]. Figure 3b illustrates that around 45% of the D12345
GST-L1 preparation forms capsomeres (i.e. the peaks
around 14 S). This is similar to wild type COPV GST-L1
capsomeres, of which roughly 50% assembles into capso-
meric structures (Figure 3c and [7]). To confirm that the
structures with the predicted S value for capsomeres
retained the morphological characteristics of capsomeres,
TEM analysis was performed on the peak fractions. Cap-
someres were seen in the peak fractions for both COPV
GST-L1 and D12345 GST-L1 (data not shown).
The HPV16 VLP-specific monoclonal antibody 16A binds to intact HPV16 VLPs Figure 1
The HPV16 VLP-specific monoclonal antibody 16A binds to intact HPV16 VLPs. The immunological properties of 
the HPV16 L1-specific monoclonal antibody were characterized by ELISA. Optical density values are plotted.
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Immunofluorescence microscopy of Sf9 cells infected with recombinant baculoviruses expressing wild type and chimeric L1 and  electron microscopy of wild type and chimeric VLPs Figure 2
Immunofluorescence microscopy of Sf9 cells infected with recombinant baculoviruses expressing wild type 
and chimeric L1 and electron microscopy of wild type and chimeric VLPs. a, A diagram of the relative positions, 
corresponding amino acids and numerical designations for the 5 hypervariable regions of the surface-exposed loop domains of 
L1. For each aligned amino acid sequence shown, HPV16 L1 is represented above the appropriate COPV L1 sequence; the 
amino acid positions of the 5 HPV16 sequences are indicated as superscripts. For example, in the all five loop swap D12345 
GST-L1, each of the 5 hypervariable HPV16 L1 domains replaces the corresponding COPV L1 hypervariable domains on a 
COPV L1 backbone. The COPV L1 backbone is not shaded. The hypervariable regions of L1 are numbered and shaded black. 
These fall within the surface-exposed loop domains, which are checkered gray. b, Electron micrographs of wild type and chi-
meric VLPs are shown. Size bar represents 50 nm. In the BB22 and BB23 L1 diagrams, the hatched regions represent the 
swapped COPV L1 amino acids. The hypervariable regions are designated as thick black lines. The HPV16 L1 portions are 
unshaded. c, d, Sf9 cells were seeded onto coverslips in plastic plates and infected with the designated recombinant baculovi-
ruses for 3 days. Immunofluorescence microscopy was performed as described in the text. c, Samples stained with conforma-
tion-independent antibody, anti-AU1, were used as a control for protein expression; HPV-16 L1 protein was used as a positive 
control for the various antibody reactions. d, Immunofluorescence with monoclonal antibody 16A.
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D12345 GST-L1 forms capsomeres as demonstrated by two independent techniques and retains immunoreactivity with mono- clonal antibody 16A Figure 3
D12345 GST-L1 forms capsomeres as demonstrated by two independent techniques and retains immunoreac-
tivity with monoclonal antibody 16A. a, TEM of D12345 GST-L1 showing capsomere formation. TEMs of COPV GST-L1 
and HPV16 GST-L1 capsomeres included for reference. Size bars represent 100 nm. b, Immunoblot of D12345 sucrose density 
gradient fractions with anti-AU1, with peaks for protein sedimentation markers indicated as arrows and corresponding densit-
ometry analysis shown below. c, COPV GST-L1 as positive control. Immunoblot of COPV GST-L1 sucrose density gradient 
fractions with with anti-AU1. Standards are indicated as in b, and corresponding densitometry analysis is shown below. The 
amount of GST-L1 in the fractions was plotted as the percentage of total GST-L1 protein. Protein standards used were hemo-
globin (4.5 S), catalase (11 S) and beta-galactosidase (19 S). d, Quantitative ELISA testing the immunoreactivity of D12345 GST-
L1, HPV16 GST-L1 (positive control) and COPV GST-L1 (negative control) with the anti-HPV16 VLP monoclonal antibody 
16A. A representative example of 2 independent experiments is shown.
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As shown in figure 3d, 16A was comparably immunoreac-
tive with HPV16 GST-L1 and D12345 GST-L1. By contrast,
COPV GST-L1 was not recognized by 16A. This indicated
that the 16A epitope was present within the HPV16 L1
hypervariable loop regions, as the homologous replace-
ment of the COPV L1 hypervariable regions with those of
HPV16 L1 transferred immunoreactivity to the chimeric
L1 molecule.
The hypervariable regions recognized by 16A are located 
on loops I and possibly II
In order to delineate the HPV16 L1 hypervariable regions
recognized by 16A, a panel of COPV-HPV16 L1 mutants
was constructed, purified and characterized (Figure 4a).
The electron micrograph for each mutant demonstrated
capsomeric structures of the same size, and morphology
as seen previously with COPV GST-L1, HPV16 GST-L1
and D12345 GST-L1 (data not shown). The sucrose gradi-
ent sedimentation profiles are comparable to D12345
GST-L1, with 58–71% of the various mutants from each
preparation assembling into structures with the same S
value as COPV GST-L1 capsomeres (Figure 4a and data
not shown).
The immunoreactivities of all these capsomeric prepara-
tions were measured by ELISA. The various loop swap
mutants D12345 GST-L1, D1234 GST-L1, D123 GST-L1
and D12 GST-L1 retained virtually identical immunoreac-
tivity with 16A and displayed reaction kinetics that were
comparable to HPV16 GST-L1 (Figure 4b). However,
D234 GST-L1 was not reactive with 16A. These results sug-
gest that HPV16 L1 loop domains I and possibly II display
critical components of the type-specific, conformational
epitope.
Discussion
Characterization of surface, conformation-dependent
antigenic epitopes on the papillomavirus capsid is impor-
tant for understanding early virus/host interactions and
for the development of effective papillomavirus vaccines.
Due to their discontinuous nature, mapping these confor-
mational epitopes has been very difficult. However, the
sequence homology between the different types of papil-
lomavirus L1 proteins together with the recently pub-
lished crystallographic model provide a methodology for
mapping the conformational epitopes by a domain swap
approach.
To evaluate the role of these various domains in the for-
mation of type-specific, conformational epitopes, we used
the domain swap approach to construct both gross and
discrete HPV16-COPV L1 chimeras. Initial experiments
indicated that the hypervariable regions within the first
169 residues of HPV16 L1 might contain the 16A epitope,
however the participation of other HPV16 L1 residues in
the formation of this epitope could not be ruled out.
The next approach chosen to study the L1 loop domains
was to swap out the 5 hypervariable regions of COPV L1
and homologously replace them with the 5 corresponding
hypervariable regions of HPV16 L1. Once the construc-
tion of D12345 GST-L1 was complete, the structural prop-
erties of this mutant needed to be characterized, as the
complexity of L1 protein folding makes accurate predic-
tions regarding assembly difficult. Gross morphological
analysis by TEM demonstrated that D12345 GST-L1
assembles into capsomeres. The sucrose density gradient
experiments were subsequently used as a more stringent
method of structural analysis and revealed obvious differ-
ences in the gradient profiles of wildtype COPV GST-L1
compared to D12345 GST-L1 capsomeres. Although both
are bimodal, D12345 GST-L1 contains structures that
peak after 19 S, whereas the second peak for COPV GST-
L1 is toward the pellet. This suggests that structural altera-
tions occur when the HPV16 L1 loops replace those of
COPV, and this may account for the different sedimenta-
tion profiles. Perhaps the heavier structures found in frac-
tion 10 contain different L1 monomer packing
characteristics such that their density is greater and/or that
their size and/or shape is altered. Protein preparation het-
erogeneity might also play a factor, and this becomes a
more likely candidate explanation when the gradient
profiles of the loop swap mutant panel are taken into con-
sideration. Depending on both the mutant as well as the
preparation, 50–71% of the proteins in the various sam-
ples assemble into structures with the S values predicted
for capsomeres, demonstrating the variable contribution
made by protein in the second peak to the total protein in
the sample. Due to technical difficulties, it was not possi-
ble to analyze the immunological properties of the vari-
ous sucrose gradient fractions. As both TEM analysis (data
not shown) and Western blotting of the various fractions
indicate that capsomeres assemble (Figure 4a and data not
shown), and because chromatography-purified GST-L1
proteins are immunoreactive with L1-specific conforma-
tion-dependent antibodies, further investigation into the
etiology of the bimodal peaks was not pursued. Although
it might be argued that the chromatography fractions con-
tain mixtures of both capsomere and non-capsomere frac-
tions and that this may somehow affect conformation-
dependent antibody-binding, this is not likely. If any-
thing, slight structural perturbations would have a nega-
tive impact on conformational epitope presentation.
Thus, while the loop swap mutants display characteristics
that might be attributed to something biologically rele-
vant, such as altered assembly properties, or to something
insignificant, such as preparation heterogeneity, it should
be emphasized that regardless of the properties of the
heavier structures, at least 50% of the various purifiedBMC Microbiology 2004, 4:29 http://www.biomedcentral.com/1471-2180/4/29
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An anti-HPV16 VLP type-specific monoclonal antibody recognizes a conformation-dependent epitope presented by loops I and  II Figure 4
An anti-HPV16 VLP type-specific monoclonal antibody recognizes a conformation-dependent epitope pre-
sented by loops I and II. a, Capsomere assembly was verified via SDG analysis and by TEM (data not shown). Percent cap-
somere assembly was determined as per SDG approach with final results as indicated. b, Quantitative ELISA testing the panel 
of loop swap mutants, HPV16 GST-L1 (positive control) and COPV GST-L1 (negative control) with anti-HPV16 VLP mono-
clonal antibody 16A.
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mutants contain structures with the expected sedimenta-
tion coefficient for wild type capsomeres, and this is
comparable to the result obtained with COPV GST-L1
(also see [7]).
16A was not immunoreactive with COPV GST-L1. There-
fore, the transference of immunoreactivity of 16A to
D12345 GST-L1 confirmed that the 16A epitope is located
within the HPV16 L1 hypervariable regions. In D234 GST-
L1, the replacement of HPV16 hypervariable region I with
COPV hypervariable region I abolished 16A immunoreac-
tivity, implicating the first hypervariable region of HPV16
L1 in epitope presentation. However, it did not rule out
that the second hypervariable region might also contrib-
ute to antibody binding. To conclusively demonstrate that
the epitope of 16A is located within the hypervariable
regions I and II of HPV16 L1, this would require a lack of
immunoreactivity of 16A with D1 GST-L1. Due to
technical difficulties, we were unable to purify mutants
containing HPV16 loop I but lacking HPV16 loop II. Mul-
tiple attempts were made to purify such mutants, includ-
ing D1 GST-L1, D15 GST-L1 and D13 GST-L1, but the
yields were extremely poor. Extensive precipitate forma-
tion was seen with these mutants after overnight dialysis,
indicating that these mutants were adopting non-native
conformations. Attempts to modify various conditions in
the purification protocol all proved unsuccessful. The dif-
ficulties in purifying loop swap mutants containing
HPV16 domain I but lacking HPV16 domain II suggest
that a crucial, structural interaction may occur between
HPV16 domains I and II such that successful protein fold-
ing of any loop swap mutant containing HPV16 domain I
requires that HPV16 domain II also be present. This inter-
action may be biologically relevant or it may have to do
with the margins chosen for the hypervariable domain
swaps.
The loss of immunoreactivity when HPV16 L1 domain I is
removed supports the conclusion that a component of the
16A epitope is found within domain I. However, it does
not rule out that HPV16 L1 domain II does not play a role.
Thus, the hypervariable regions within loop domains I
and possibly II display a type-specific, conformational
epitope, complementing the results of earlier studies
[14,26-33,42-44].
This is the first study to simultaneously swap multiple
hypervariable regions of HPV16 onto a completely diver-
gent L1 backbone. Because papillomavirus L1s are so
homologous, even when comparing human to those from
other animals, mapping studies may have signal-to-noise
ratios potentially influenced by the selected L1 backbone.
If, for example, a particular HPV6 epitope is mapped, it
should be swapped onto a distantly related HPV L1 or
other animal papillomavirus L1 as performed by others
[33].
Theoretically, using a less related L1 backbone may allow
one to rule out the possibility that other amino acids,
which are more conserved between certain HPVs, might
modulate antibody binding. However, it has also been
shown that certain HPV11-CRPV L1 hybrids failed to
assemble into VLPs indicating that some L1 combinations
might be too disparate to direct proper folding of the L1
molecule [32]. This may account for our observation that
HPV16 domain II was necessary for successful purification
of our COPV-HPV16 L1 hybrids.
Conclusion
These results from our study suggest that non-contiguous
loop regions of L1 display critical components of a type-
specific, conformational epitope. This study further con-
firms that domain swapping is a useful approach to study
and map the components of potential type-specific
epitopes, complementing the results of others [28,32,33].
However, much remains to be learned about the loop
epitopes, their contribution to type-specificity and their
interaction with the host immune system prior to the con-
struction of a hybrid VLP molecule capable of inducing
multiple cross-neutralizing antibodies. This study also
used the crystallography data to rationally design the
swapping experiments and like other studies [20,32,34-
37], it further supports the biological relevance of the
recently proposed VLP structural model [25]. The GST-L1
system is also novel, and its capabilities were previously
unknown. The results of this study also demonstrate that
studying capsomeric epitopes in this system is possible.
Methods
Cell culture
Sf9 cells were cultured in 1X Grace's Medium Supple-
mented (GIBCO/BRL) containing 10% fetal bovine serum
and 10 ug/ml of gentamicin (GIBCO/BRL).
DNA constructs: HPV16/COPV chimeric VLP mutants
The parental baculovirus transfer plasmid pBlueBac IV
(Invitrogen) contained either the wild type 114 K HPV16
L1 ORF (pBB114K) or the COPV L1 ORF (pBBCOPVL1).
The COPV L1 sequence was amplified by using primers:
5'-ACTGTTTTCGTAACAGTTTTG-3', 5'-ACATGGGGATC-
CTTTGCCCCAGTGTTCACCTAAAGCTGG-3'. The PCR
product was digested with Xho I and Bam H1 and reli-
gated into Xho I – Bam H1 site of pBB114K, resulting
pBB22. The mutant pBB23 was created by replacing the
EcoR I – Hind III fragment of pBB114K with the corre-
sponding sequence from wild type COPV L1 gene. The
primers are 5'-TTCTATGAATTCCACTATTATTGAGGATT-
GGCACCTA-3' and 5'-GGGAAGCTTCACAAGTAATC-3'.
The PCR product was digested with EcoR I and Hind IIIBMC Microbiology 2004, 4:29 http://www.biomedcentral.com/1471-2180/4/29
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and religated into EcoR I – Hind III sites of pBB114K. All
clones were verified by dideoxy-DNA sequencing. The
pGEX-4T-2-HPV16 L1 construct was a kind gift from the
Garcea laboratory. The COPV L1 gene was cloned into the
pGEX-4T-2 vector (Amersham Pharmacia Biotech, Piscat-
away NJ) as previously described [7].
Construction of various loop swaps
With slight modifications, the general protocol for assem-
bly PCR was used [45]. For the various loop swaps con-
structed, restriction enzyme sites unique to COPV L1 and
absent from both pGEX-4T-2 vector and the HPV16 L1
loops were used. These sites flank the various hypervaria-
ble regions and are as follows. StyI and MunI flank loops
I-III, MunI and StuI loop IV, and StuI and BseRI loop V.
The 40 mer primer sets were designed so that as many as
possible could be incorporated into multiple cDNA syn-
thesis reactions. For example, the 40 mer oligonucleotides
for any potential permutation of the D123 swap (i.e. D12;
D23; D13, etc.) spanned the restriction sites StyI to MunI.
The strategy for staggering the 40 mers for this fragment of
the L1 gene took into account that the intervening wild
type sequences between the hypervariable regions would
be common to any D123 swap combination. The design
of the D4 and D5 primer sets was more straightforward.
For each of these loop swaps, the 40 mers spanned MunI
to StuI for D4 and StuI to BseRI for D5. Once all the possi-
ble D123 combinations, D4 and D5 were cloned, any pos-
sible permutation of the HPV16 and COPV L1 loop
domains could be constructed by simple cutting and past-
ing directly into pGEX-4T-2 COPVL1. All primers were
synthesized by Life Technologies (Rockville MD).
Following completion of Step 2, the PCR product was
ligated with the pGEM-T vector (Promega, Madison WI)
for sequencing confirmation. Following such confirma-
tion, the COPV-HPV16 L1 hybrid loop gene fragments
were then digested and inserted into the appropriate sites
in the predigested pGEX-4T-2 COPV L1 construct. Positive
clones were identified via bi-directional sequencing using
primers (Life Technologies, Rockville MD), which were
designed with the ability to sequence multiple mutants
(i.e. the various primers hybridize with wild type COPV
L1 sequences located in between the hypervariable
regions). All the primer sequences will be provided upon
request.
Production and purification of virus-like particles and 
GST-recombinant protein
VLPs were prepared as described previously [38]. GST-
fusion proteins were purified as described elsewhere [41].
ELISAs
100 ng of VLPs or 50 ul of GST-fusion protein per well was
used for ELISA as described previously ([38]or [7]respec-
tively). The monoclonal antibody 16A [39] (Rumbaugh-
Goodwin Institute, Plantation FL) was used at 1:50 dilu-
tion. The secondary antibody, horseradish peroxidase
(HRP)-conjugated anti-mouse IgG (Santa Cruz, Santa
Cruz CA), was used at 1:1000 dilution.
Immunofluorescence assay
Insect Sf9 cells were seeded on coverslips at 50% conflu-
ence and infected with the designated recombinant bacu-
loviruses for three days before fixation with ice-cold
acetone. After fixation, the coverslips were incubated with
the monoclonal antibody anti-AU1, a conformation-inde-
pendent monoclonal antibody that recognizes a 6 amino
acid epitope found at the C-terminus of many different
papillomavirus L1 proteins, at 1:125 (Covance, Rich-
mond CA), or 100 ul of 16A, a conformation-dependent,
serotype-specific monoclonal antibody [39]. After 3
washes, the coverslips were reacted with rhodamine-con-
jugated goat anti-mouse IgG/IgM diluted 1:50 (v/v) in
PBS for 1 hour. After washes with PBS, the coverslips were
mounted on glass slides with Fluoromount (PanData,
Rockville, MD) mounting solution. Cells were viewed and
photographed with a Zeiss Axioskop inverted fluores-
cence microscope.
Western blots
Sf9 cells were harvested by centrifugation and solubilized
in sample buffer. Bacteria with GST-L1 recombinant pro-
teins were pelleted and lysed in 100 ul of SDS loading
buffer. 15 ul of the total cell extracts was then subjected to
electrophoresis in 4–20% precast gels (Invitrogen,
Carlsbad CA). Samples were then electrophoretically
transferred at to a polyvinylidenefluoride membrane
(Millipore, Bedford MA). The immunoblot analysis was
performed as described previously [7].
Electron microscopy
Ten microliters of sample was adsorbed onto carbon-
coated grids (Electron Microscopy Sciences, Fort Washing-
ton PA) and followed by counter-staining with 2% phos-
photungstic acid (pH = 6.8). A JEOL 100S electron
microscope was used for visualization at 60 kV. Electron
micrographs were taken at 50,000× or 100,000×.
Sucrose density gradients
Gradients were set-up and analyzed as described previ-
ously [7].
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